Pharmacovigilance analysis of drug-induced hypertrophic rhinitis using FAERS data

Our study aims to evaluate the risk of drug-induced hypertrophic rhinitis and analyze its epidemiological characteristics utilizing real-world data. We employed reporting odds ratios (ROR) to assess the disproportionality in reports of drug-induced hypertrophic rhinitis between January 2004 and September 2024. Single-factor, LASSO, and multi-factor regression analyses were conducted to investigate drugs associated with hypertrophic rhinitis. The Bonferroni correction was implemented to conduct multiple comparisons. 250 drugs were linked to hypertrophic rhinitis, with 85 drugs (case number > 100) identified as independent risk factors for drug-induced hypertrophic rhinitis. Those drugs' indications were classified as Allergic disease (19/85), Multi-indication (13/85), Cardiovascular disease (12/85), Rheumatoid disease (6/85), Autoimmune disease (6/85), Respiratory disease (5/85), Cancer (4/85), Metabolic disease (4/85), Contrast agent (3/85), Erectile dysfunction (3/85), Infection (3/85), Disease of the nervous system (2/85), Urologic Disease (2/85) Esophageal disease (1/85), Hereditary disorder (1/85), and Ophthalmic disease (1/85). Multiple medications have possible risks of drug-induced hypertrophic rhinitis. Further research is needed to clarify causality and guide clinical decision-making.